Business
Jaguar Health Subsidiary Napo Pharmaceuticals Enters ex-U.S. Distribution Agreement for Mytesi (Crofelemer) with TannerGAP, Inc.
SAN FRANCISCO, CA / ACCESSWIRE / October 30, 2019 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company"), today announced that the Company's
About this update from Jaguar Health, Inc.
[{"type":"text","content":"SAN FRANCISCO, CA / ACCESSWIRE / October 30, 2019 / Jaguar Health, Inc. (NASDAQ:JAGX) (\"Jaguar\" or the \"Company\"), today announced that the Company's wholly-owned subsidiary, Napo Pharmaceuticals, Inc. (\"Napo\"), has entered into a two-year distribution agreement (\"the Agreement\") with TannerGAP, Inc. (\"Tanner\"), a division of Tanner Pharma Group, a global provider of integrated specialty access solutions. The Agreement names Tanner as a distributor of Mytesi® (crofelemer) on a named patient supply basis outside of the United States, Canada and Israel in regions where the product is not yet registered.\"Our ongoing commitment is to enhance Mytesi (crofelemer) access for people living with HIV - across all populations, all countries, and we believe this agreement will help accelerate that access to Mytesi on a named patient access basis in underserved international markets,\" Lisa Conte, Jaguar's president and CEO commented. \"Tanner possesses extensive knowledge and experience in the distribution of pharmaceutical products on a global basis, including the servicing of requests for a particular medicine in markets where that medicine is not licensed.\"Maryori Alvarenga, Managing Director of US of Tanner Pharma Group, commented, \"We are pleased to be working with Napo to expand the distribution of Mytesi (crofelemer) to patients in need around the world. TannerGAP has a strong track record of success in working with physicians, hospitals and ministries of health to provide medicine that is not currently available in their country.\"Jaguar's Mytesi (crofelemer) product is approved by the U.S. Food and Drug Administration for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. There have been requests outside the US for named patients in need outside the US.About Mytesi®Mytesi (crofelemer) is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART). Mytesi is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting Mytesi. If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical studies, the most common adve...